1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Ipsen Dives Back Into Dealmaking With First ADC Pact

 
• By Kevin Grogan

The French drugmaker has teamed up with South San Francisco's Sutro Biophgarma to bag the rights to a preclinical-stage ADC targeting ROR1.

Ipsen
• Source: Alamy

Ipsen SA has resumed its oncology shopping spree and moved into the antibody-drug conjugate (ADC) space for the first time by linking up with Sutro Biopharma, Inc. of the US.

The French mid-sized pharma has inked a deal that could be worth up to $900m, including $90m in near-term payments...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 
• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

AstraZeneca And Daiichi Sankyo’s Datroway Scores Survival Success In TNBC

 
• By Andrew McConaghie

Its overall survival win for Datroway could be an advantage over Gilead’s Trodelvy in triple negative breast cancer.

Jazz Looks To Label Expansion To Reverse Zepzelca Sales Slump

 
• By Alaric DeArment

The FDA approved the drug for combination with Roche’s Tecentriq in first-line maintenance of extensive-stage small cell lung cancer, while the NCCN added the combination to its treatment guidelines.

Attractiveness of Cell Therapy In The Spotlight With Limited Interest In Galapagos Unit

 
• By Kevin Grogan

Non-binding offers have come mostly from groups of financial investors rather than biopharma players.

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.